Macular Edema and Macular Degeneration Market Report 2026

The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $10.33 billion in 2025 to $11.03 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing prevalence of diabetes and retinal disorders, aging population with higher vision impairment risk, clinical success of anti-vegf injections, growing awareness of macular diseases, expansion of ophthalmology clinics.

The macular edema and macular degeneration market size is expected to see strong growth in the next few years. It will grow to $14.33 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising global diabetic population, increasing screening for retinal diseases, growing demand for minimally invasive eye treatments, expanding access to advanced ophthalmic care, higher healthcare spending on vision preservation. Major trends in the forecast period include rising adoption of anti-vegf based therapies, growing demand for early diagnosis and intervention, increasing use of combination drug and laser therapies, rising focus on managing diabetic eye complications, expansion of outpatient and clinic-based eye care.

The increasing diabetes population is anticipated to drive the growth of the macular edema and macular degeneration market in the coming years. Diabetes is a chronic health condition marked by elevated blood glucose (sugar) levels. It damages the blood vessels in the eyes, potentially leading to macular edema and macular degeneration. For example, in June 2024, according to The National Health Service (NHS England), a UK-based publicly funded healthcare system, the number of individuals identified with pre-diabetes in England rose to 3,615,330 in 2023, reflecting an 18% increase from 3,065,825 in 2022. Furthermore, among those under 40, cases increased nearly 25%, rising from 173,166 in 2022 to 216,440 in 2023. Consequently, the growing diabetes population is fueling the expansion of the macular edema and macular degeneration market.

Major companies in the macular edema and macular degeneration market are concentrating on developing innovative products, such as continuous-delivery ocular implants, to reduce treatment burden, improve patient adherence, and provide more consistent long-term therapeutic outcomes. Continuous-delivery ocular implants are small, refillable devices implanted in the eye that gradually release medication over several months, reducing the need for frequent injections and offering steady, long-term treatment for retinal diseases. For example, in February 2025, F. Hoffmann-La Roche Ltd, a Switzerland-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for Susvimo, a refillable ocular implant delivering the anti-VEGF drug ranibizumab for diabetic macular edema (DME). Susvimo is designed as a long-acting, surgically implanted reservoir that continuously releases a customized formulation of ranibizumab, maintaining therapeutic drug levels for extended periods. Unlike traditional anti-VEGF intravitreal injections, which often require monthly or bi-monthly dosing, Susvimo offers a refill-exchange interval of approximately six months, significantly reducing patient treatment burden. Its sustained-delivery mechanism enhances adherence, streamlines clinical workflow, and provides durable anatomical and visual benefits for patients with chronic retinal disease.

In July 2024, Merck & Co., Inc., a U.S.-based pharmaceutical and biotechnology company, acquired Eyebiotech Limited (Eyebio) for an undisclosed amount. The acquisition aims to strengthen and diversify Merck’s late-stage pipeline by adding Restoret, a novel late-phase candidate for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD). This acquisition expands MSD’s portfolio with innovative treatments based on novel biology and genetics, addressing unmet medical needs in retinal diseases. Eyebiotech Limited (Eyebio) is a U.S.-based ophthalmology biotechnology company that develops therapies to treat sight-threatening eye conditions, including macular edema and macular degeneration.

Major companies operating in the macular edema and macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co Ltd, Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Kodiak Sciences Inc., Opthea Limited, IVERIC bio Inc., Neurotech Pharmaceuticals Inc., Regenxbio Inc., Graybug Vision Inc., Clearside Biomedical Inc., Kubota Pharmaceutical Holdings Co Ltd, Acucela Inc., PanOptica Inc., Ocugen Inc.

North America was the largest region in the macular edema and macular degeneration market in 2025. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the macular edema and macular degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the macular edema and macular degeneration market by raising costs for imported anti-vegf drugs, laser therapy equipment, and ophthalmic consumables. These impacts are most evident in drug therapy segments and advanced laser treatment solutions, particularly across asia-pacific and europe where supply chains rely on cross-border sourcing. Hospitals and clinics face higher procurement and treatment costs as a result. However, tariffs have encouraged local manufacturing of ophthalmic drugs, regional production of laser devices, and supply chain diversification, supporting long-term market stability.

The macular edema and macular degeneration market research report is one of a series of new reports that provides macular edema and macular degeneration market statistics, including macular edema and macular degeneration industry global market size, regional shares, competitors with a macular edema and macular degeneration market share, detailed macular edema and macular degeneration market segments, market trends and opportunities, and any further data you may need to thrive in the macular edema and macular degeneration industry. This macular edema and macular degeneration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Macular edema and macular degeneration are two distinct eye conditions that can impact vision. Macular edema involves swelling in the part of the retina at the back of the eye, which may result in blurry vision. Macular degeneration affects the macula, a portion of the retina responsible for central vision. These conditions can arise from various factors, including diabetic retinopathy, retinal vein occlusion, and inflammation, as well as age, genetics, smoking, high blood pressure, and obesity.

The primary treatments for macular edema and macular degeneration include drug therapy and laser treatment. Drug therapy involves the use of pharmaceutical drugs or medications to treat, manage, or relieve medical conditions, diseases, or symptoms in individuals. It is applied for conditions such as macular edema, diabetic macular edema (DME), cystoid macular edema (CME), macular degeneration, dry age-related macular degeneration, and wet age-related macular degeneration by hospitals, clinics, and other healthcare providers.

The macular edema and macular degeneration market consists of revenues earned by entities by providing services such as ophthalmic care, ophthalmologic evaluation, imaging and diagnostics, laser therapy, photodynamic therapy, and rehabilitation and low vision services. The market value includes the value of related goods sold by the service provider or included within the service offering. The macular edema and macular degeneration market also includes sales of surgical interventions, low vision aids, dietary supplements, retinal implants, and subretinal injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.